<DOC>
	<DOCNO>NCT01226030</DOCNO>
	<brief_summary>This study dose-escalation open-label study determine MTD M2ES Subjects With Advanced Solid Tumors recommend Phase II dose.The recommend dose regimen M2ES select perform pharmacokinetic study profile .</brief_summary>
	<brief_title>Dose Escalation PK Study M2ES Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description>This study Phase I dose-escalation open-label study determine MTD M2ES Subjects With Advanced Solid Tumors recommend Phase II dose.The recommend dose regimen M2ES select perform pharmacokinetic study profile .</detailed_description>
	<criteria>1 . 18 60 year age 2. patient histologically cytologically confirm solid tumor refractory standard therapy . 3. life expectancy least 3 month . 4 . ECOGPS ≤ 1 5 . Adequate hematologic , renal , hepatic function require determine follow : WBC ≥4×109/L , absolute neutrophil count ≥ 1.5×109/L , platelet count ≥100×109/L , hemoglobin ≥ 9g/dL , total bilirubin ≤1.5 upper limit normal [ ULN ] , AST ≤ 2.5 ULN , ≤ 5 ULN evidence liver metastasis ; alkaline phosphatase ≤ 2.5 ULN , ≤ 5 ULN evidence liver Metastases ; creatinine clearance ≥50 mL/min . 1 . Pregnant latent woman , contraception woman childbearing age 2 . Have take treatment 3 . Be allergic endostatin ingredient 4 . Gastrointestinal Hemorrhage 5 . Have Participated clinical trail last 4 week 6 . ECG : QTC ≥ 480 m 7. patient clinically apparent CNS disease ( primary brain tumor , tumor relate apoplexy , CNS metastases , carcinomatous meningitis . ) 8 . Cardiovascular mental disease 9 . HIV1 infect 10 . HBV , HBV infect , Hepatitis B surface antigen positive 11 . Patients therapeutic dos heparin antiplatelet agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Advanced Solid Tumors</keyword>
</DOC>